Research shows that a panel of UK medical experts has agreed on consensus recommendations for using semaglutide to treat obesity in children and young people in England. The guidance, published in 2026 in Archives of Disease in Childhood, pairs medication with lifestyle support, careful safety monitoring, and specialist care. According to research reviewed by Gram, these statements reflect expert agreement rather than new trial results.
According to research reviewed by Gram, a panel of UK specialists has agreed on guidance for using semaglutide, a weight-loss medicine in the same family as the diabetes drug Ozempic, to treat obesity in children and young people in England. Published in Archives of Disease in Childhood in 2026, the work used a Delphi-like process, in which experts privately rated statements over several rounds until they reached agreement. The statements focus on who may be a good candidate, the need for lifestyle support alongside medicine, careful safety monitoring, and regular check-ins with specialist teams. The findings do not test whether the medicine works in a clinical trial. Instead, they reflect expert judgment, which can guide clinicians while larger studies continue to answer open questions about long-term safety and benefits.
Key Statistics
A 2026 Delphi-style expert consensus published in Archives of Disease in Childhood set out recommendations for semaglutide use in children and young people in England, based on multiple rounds of anonymous expert ratings.
The consensus statements pair semaglutide with lifestyle support and ongoing monitoring, reflecting agreement reached among UK specialists rather than new clinical trial results.
The Quick Take
- What they studied: How doctors and specialists in England should use semaglutide, a weight-loss medicine, to treat obesity in children and young people.
- Who participated: A panel of UK medical specialists with experience in treating young people with obesity. The exact number of participants was not specified in the available information.
- Key finding: The experts reached agreement on a set of statements describing how semaglutide may be used safely in young people, including combining it with lifestyle support and regular monitoring. These statements reflect expert consensus, not new trial results.
- What it means for you: If you or your child is dealing with obesity, this guidance suggests medicine may be one option, but it is usually part of a broader plan with diet, activity, and specialist care. Talk with a doctor about whether it fits your situation.
The Research Details
Researchers used a Delphi-like process, a structured way to reach agreement among experts when strong trial evidence is limited. In this method, a panel is asked to rate a series of statements about a topic. Responses are gathered, summarized, and shared back with the group, and experts then rate the statements again.
This cycle typically repeats over several rounds. Each round aims to move the group closer to a shared view. Statements that reach a set level of agreement are kept as consensus recommendations, while those that do not are revised or dropped.
Because the process relies on expert opinion, it captures what specialists believe is sensible practice today. It does not test the medicine on patients the way a randomized trial does.
Semaglutide is a newer treatment for young people, and research on children is still developing. When high-quality trial data are limited, expert consensus helps doctors and health services make consistent, careful decisions. It also highlights which questions still need answers.
Consensus studies are useful for turning expert knowledge into practical guidance, but they are not the strongest form of evidence. Their conclusions depend on who was on the panel, how statements were written, and what agreement threshold was set. Readers should treat the recommendations as informed professional judgment rather than proven outcomes. The paper was published in a peer-reviewed medical journal, which adds a layer of scrutiny.
What the Results Show
The main output of the study is a set of consensus statements about using semaglutide in children and young people with obesity in England. The statements address who may be considered for treatment, how it should be combined with lifestyle support, and what kind of monitoring is needed.
A key theme is that medication is generally presented as one part of a larger plan. The experts emphasized that dietary changes, physical activity, and emotional and family support remain central. Semaglutide is framed as something that may be added when appropriate, not as a standalone fix.
The statements also stress safety. Common side effects of this class of medicine, such as nausea, vomiting, and stomach upset, are likely to be discussed with families. Regular check-ins and specialist oversight appear to be important, particularly because long-term effects in younger people are still being studied.
The results should be read as expert agreement rather than proof. They offer a framework for clinical decisions, and their practical impact will depend on how they are applied in real clinics.
Beyond the core recommendations, the process highlights areas where the panel believed more evidence is needed. These include long-term safety, the best way to support families, and how treatment should be stopped, continued, or adjusted over time. Identifying these gaps is useful because it points researchers toward the questions that matter most for young people.
The guidance also reflects a concern with consistency across services. A shared framework may help reduce differences in care between clinics and regions, which can matter for families who move or who receive care from different teams.
Semaglutide has been studied in adults and in adolescents with obesity, and trial results have shown meaningful weight reduction in many participants. This consensus builds on those findings by translating them into guidance for everyday clinical practice in England. It does not replace trial evidence but adds a practical layer that trials alone do not provide.
The main limitation is that the recommendations reflect expert opinion rather than new experimental data. Experts can differ in their views, and the final statements depend on the panel’s makeup and the agreement threshold used. Because the guidance applies to England, it may not transfer directly to other health systems. Long-term outcomes for young people remain uncertain, and the guidance is expected to change as new evidence emerges.
The Bottom Line
Research reviewed by Gram suggests that semaglutide may be considered for some young people with obesity in England, but only as part of a structured plan. Confidence is moderate that the recommendations reflect current expert thinking, and lower that they predict long-term outcomes, since those are still being studied. Lifestyle support, ongoing monitoring, and specialist oversight appear to be central in every case.
Parents, young people, clinicians, and health service planners in England are the most likely to find this guidance relevant. People outside the UK should note that local rules and approvals may differ. Young people without obesity, or those for whom medication is not appropriate, will not be directly affected by these recommendations.
Medication effects, when they occur, typically develop over several months rather than days. Any benefit would usually be judged over a period of months, with regular reviews of weight, health markers, and side effects. Families should expect gradual change and ongoing check-ins rather than rapid results.
Frequently Asked Questions
Is semaglutide approved for children with obesity in England?
Semaglutide has been licensed in the UK for people aged 12 and older with obesity, and this 2026 expert consensus offers guidance on how clinicians may use it in young people. Eligibility and prescribing depend on specialist assessment and local service rules.
What did experts recommend about semaglutide for teenagers with obesity?
The 2026 expert panel recommended using semaglutide alongside lifestyle support, such as dietary and physical activity programmes, with regular safety checks and specialist oversight. The statements reflect expert agreement rather than the findings of a new clinical trial.
What is a Delphi consensus study in medical research?
A Delphi consensus study asks a panel of experts to rate statements anonymously over several rounds, sharing group feedback between rounds until they converge on agreement. Researchers use it when trial evidence is limited, so it captures expert judgment rather than proof of effectiveness.
Can semaglutide help teens lose weight, and what are the risks?
Trials in adolescents have shown semaglutide can produce meaningful weight loss, but common side effects include nausea, vomiting, and stomach upset. This expert consensus emphasizes monitoring and specialist supervision, since long-term safety in young people is still being studied.
Want to Apply This Research?
- Log body weight once a week at the same time and under similar conditions, and record any side effects such as nausea or appetite changes on a 1 to 5 scale. Share these logs at scheduled clinic visits so trends can be reviewed.
- Use the app to set one realistic, measurable lifestyle goal each week, such as adding a daily 20-minute walk or preparing one vegetable-rich meal at home. Pair medication schedules with these habits so both are visible in one place.
- Over the long term, track weight trends, energy levels, mood, sleep, and side effects in monthly summaries, and flag any changes to the care team. Keep records of appointments and lab results in one secure location so that long-term decisions can be based on a complete picture.
This article summarizes an expert consensus statement and is for general information only. It is not medical advice and does not replace consultation with a qualified healthcare professional. Semaglutide is a prescription medicine with potential side effects and eligibility criteria, so decisions about treatment for children or young people should be made with a doctor or specialist team who knows the individual’s health history.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.